Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells
- 1Department of Tumor Intervention, the Second People’s Hospital of Wuhu, Wuhu, P.R. China
- 2Department of Medical Oncology, the First Affiliated Hospital of Wannan Medical College, Wuhu, P.R. China
Abstract
Background/Aim: The clinical efficacy of sorafenib against hepatocellular carcinoma (HCC) is severely limited by limited efficacy and off-target toxicity. Overexpression of oncogenic miR-21 has been identified as a key driver of these limitations, as it downregulates the tumor suppressors PTEN and PDCD4, thereby aberrantly activating both the PI3K/Akt and STAT3 signaling pathways. To address the limitations of conventional sorafenib therapy, we aimed to construct a smart nanocarrier capable of simultaneously delivering sorafenib (SF) and anti-miR-21 specifically to HCC cells.
Materials and Methods: We designed a core-shell nanoparticle consisting of a PAMAM dendrimer/anti-miR-21 polyplex core and a hyaluronic acid-sorafenib conjugate shell. This architecture enables CD44-mediated active targeting and pH-responsive drug release in the acidic tumor microenvironment. The antitumor activity of the co-delivery system was evaluated in vitro using HepG2 cells, with assessments of cell proliferation, migration, apoptosis, and the underlying signaling pathways.
Results: The prepared nanoparticle exhibited potent anti-proliferative, anti-migratory, and pro-apoptotic effects in HepG2 cells. Mechanistic studies revealed that these benefits were associated with the reduced phosphorylation of key proteins in both the PI3K/Akt/mTOR and STAT3 cascades, effectively counteracting the therapy limitations that are normally fueled by miR-21 overexpression.
Conclusion: Our findings demonstrate that CD44-guided co-delivery of sorafenib and anti-miR-21 provides a promising nanotherapeutic strategy to counteract therapy limitations through coordinated blockade of two major oncogenic pathways in HCC cells.
Related
- Advanced Drug Delivery in Pediatric Neurology: Developmental Barriers, Nanocarrier Strategies, and Translational Challenges.
- Celastrol and Its Derivatives in Breast, Ovarian, and Cervical Cancer: Molecular Targets, Signalling Networks, and Nanocarrier-Based Delivery
- Intranasal Delivery of Gallium–Quercetin Nanoparticles for Multi‐Target Ferroptosis Inhibition in Parkinson's Disease
- Computer-Guided In-situ Screening of Poly(acetylene)s for Gene Delivery
- Artificial intelligence and machine learning-guided bio-orthogonal engineering of smart soft polymeric nanocarriers for precision drug delivery and translational nanomedicine
BibTeX
@article{lipeng2026codelivery,
title = {{Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells}},
author = {LIPENG XU and LING QIN and WENYING ZHAO},
journal = {In Vivo},
year = {2026},
month = oct,
doi = {10.21873/invivo.14493},
url = {https://doi.org/10.21873/invivo.14493},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Co-delivery of Sorafenib and Anti-miR-21 via a CD44-guided Nanocarrier for Dual-pathway Inhibition in HCC Cells
AU - LIPENG XU
AU - LING QIN
AU - WENYING ZHAO
PY - 2026
DA - 2026/10/29
JO - In Vivo
DO - 10.21873/invivo.14493
UR - https://doi.org/10.21873/invivo.14493
AB - Background/Aim: The clinical efficacy of sorafenib against hepatocellular carcinoma (HCC) is severely limited by limited efficacy and off-target toxicity. Overexpression of oncogenic miR-21 has been identified as a key driver of these limitations, as it downregulates the tumor suppressors PTEN and PDCD4, thereby aberrantly activating both the PI3K/Akt and STAT3 signaling pathways. To address the limitations of conventional sorafenib therapy, we aimed to construct a smart nanocarrier capable of simultaneously delivering sorafenib (SF) and anti-miR-21 specifically to HCC cells. Materials and Methods: We designed a core-shell nanoparticle consisting of a PAMAM dendrimer/anti-miR-21 polyplex core and a hyaluronic acid-sorafenib conjugate shell. This architecture enables CD44-mediated active targeting and pH-responsive drug release in the acidic tumor microenvironment. The antitumor activity of the co-delivery system was evaluated in vitro using HepG2 cells, with assessments of cell proliferation, migration, apoptosis, and the underlying signaling pathways. Results: The prepared nanoparticle exhibited potent anti-proliferative, anti-migratory, and pro-apoptotic effects in HepG2 cells. Mechanistic studies revealed that these benefits were associated with the reduced phosphorylation of key proteins in both the PI3K/Akt/mTOR and STAT3 cascades, effectively counteracting the therapy limitations that are normally fueled by miR-21 overexpression. Conclusion: Our findings demonstrate that CD44-guided co-delivery of sorafenib and anti-miR-21 provides a promising nanotherapeutic strategy to counteract therapy limitations through coordinated blockade of two major oncogenic pathways in HCC cells.
SN - 0258-851X
SN - 1791-7549
ER -